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Pain in SCN4A mutated p.A1156T muscle sodium channelopathy - a postal survey  
 
Abstract  
Introduction: The p.A1156T mutation alters the function of the voltage gated sodium channel Nav1.4 on the 
muscle sarcolemma, causing a channelopathy without overt myotonia or periodic paralysis but with myalgic pain. 
 
Methods: A postal survey was conducted to assess the prevalence and characteristics of pain and related 
symptoms in persons with the p.A1156T mutation. A specific questionnaire, intensity and interference subscales 
of the Brief Pain Inventory, pain drawing, Widespread Pain Index, quality of life (RAND-36), and the Beck 
Depression Inventory were completed.  
 
Results: Twenty of 24 patients replied. Current pain was reported by 16 responders; the other 4 had experienced 
pain previously. Most commonly, pain was widespread and exercise-induced. The severity and the impact of pain 
on daily life were considerable although variable. 
 
Discussion: This sodium channelopathy is another entity in the growing number of diseases causing widespread 
myalgic pain that resembles the pain seen in fibromyalgia syndrome. 
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Introduction 
Mutations of the skeletal muscle sodium (SCN4A) and chloride (CLCN1) channels can lead to non-dystrophic 
myotonias and other rare myotonic disorders.1 More than 40 different mutations, typically dominant missense, of 
SCN4A have been characterized to date2. Identical SCN4A mutations, however, can be observed in patients with 
different clinical phenotypes, indicating considerable heterogeneity in the genotype-phenotype correlations. 2-4 A 
nucleotide change c.3466G>A in exon 19 of the SCN4A causes the amino acid change p.A1156T in domain III of 
the alpha subunit of the voltage-gated sodium channel Nav1.4.5,6 The alpha subunit, coded by the gene SCN4A 
located at the chromosome 17q23-25, facilitates ion transport through the cell membrane. 
 
The p.A1156T mutation has been described in one Finnish family and two South-Korean patients who shared 
features of hyperkalemic periodic paralysis and paramyotonia congenita.5,6 We recently reported a series of 30 
new patients with this mutation, and described the clinical consequences of this mutation. These patients 
presented with widespread pain, muscular stiffness and exercise and cold-induced cramps, but without signs of 
clinical myotonia, paramyotonia or periodic paralyses.7 According to the ExAC database, the frequency of the 
p.A1156T mutation in the Finnish population is 60/100 000, meaning that there are more than 3000 mutation 
carriers and (due to the adult onset of symptoms) approximately 1000 affected individuals in Finland.7 
 
Muscular pain is a frequent symptom in non-dystrophic myotonias, as reported by approximately 80 % of the 
patients.8,9 The severity of symptoms of SCN4A related myotonias can vary from very mild ones producing 
minimal or no interference with daily life to ones that have a severe impact.9 
 
The aim of this postal survey was to assess the prevalence, characteristics, and severity of pain, muscular, and 
depressive symptoms and quality of life, in patients with the p.A1156T mutation-associated sodium 
channelopathy. 
 Materials and Methods 
A postal survey was conducted in spring 2016. The study was approved by the local ethics committee and all 
participants gave written informed consent. The reporting of this study conforms to the STrengthening the 
Reporting of OBservational studies in Epidemiology Statement (STROBE).10 
 
Participants. The study population consisted of all traceable Finnish patients with p.A1156T mutation-associated 
sodium channelopathy, in whom the diagnosis had been verified by molecular genetic methods through spring 
2016 (n=29).7 One person was excluded due to cognitive impairment, one person was under 18 years old and 3 
persons could not be contacted by mail. Hence, 24 persons were asked to participate in the survey.  
 
Questionnaires. A questionnaire was developed for this survey. It contained the following validated items: 1) Pain 
intensity and interference subscales of the Brief Pain Inventory11; 2) pain drawings (body maps) and Widespread 
Pain Index (WPI)12 (range of scores 0 to 19); 3) the Finnish version of the RAND 36-item Short Form Health Survey 
(RAND-36)13; 4) the Finnish modification of the short form of the Beck Depression Inventory (RBDI)14. 
 
Sociodemographic background, the occurrence of muscular pain, headache and gastrointestinal symptoms, non-
painful muscular symptoms (unpleasant muscular sensations, weakness, stiffness, and difficulties in initiating or 
controlling movements), factors alleviating and exacerbating pain, and current pain medication were assessed. 
Designed for the purpose of this study, numerical rating scale (NRS) of 0–10 (0 = ‘‘no symptoms’’ 10 = ‘‘the worst 
possible intensity of the symptom’’), multiple choice and open questions were used in the assessment. If 
applicable, an NRS score of 4 was chosen as the lower limit for moderate symptom intensity, because it is most 
commonly accepted for clinical use.15 We used similar approach in a previous survey of pain in myotonic 
dystrophy type 2.16 Finnish language copies of this questionnaire are available from the author upon request. See 
supplementary materials for further details. 
Statistical Analysis. Descriptive statistics, including medians and the first and third quartiles (i.e. interquartile 
range, IQR) were calculated using IBM SPSS Statistics for Macintosh, Version 24. We used one sample t-test for 
statistical comparison of mean QoL-values between the study sample and the general population. Because the 
population values were expressed as means, one sample t-test was used for this purpose, although RAND-36 
subscales rarely conform to a normal distribution.17 The alpha-level was set at 0.05 for all tests. No adjustment 
was made for multiple testing. 
 
Results 
The response rate was 20/24 (83%). Table 1 shows demographic and clinical characteristics of the respondents. 
Pain was located over the limbs or trunk in 15/20 respondents (Figure). In 8/20 drawings, pain was bilaterally 
symmetric in all 21 defined areas. Median WPI was 8.5 (IQR 5-11.75), and WPI> 7 was reported by 14/ 20 
responders. Pain intensity was highest in the areas of low back and lower limbs (median pain intensity for both 
was 6 on the NRS). Pain was increased by exercise in 78 % and cold in 50 % of patients, whereas pain was relieved 
by rest in 83 % and warmth in 61 %. Most respondents (16 / 20) reported multiple types of pain. 
 
Unpleasant muscular sensations, muscle weakness, stiffness, and difficulties in initiating or controlling 
movements with intensity of NRS 4 or above were reported by 15 (75%), 13 (65%), 15 (75%), and 14 (70%) 
respondents, respectively.  Headache occurring several days a week was reported by 6 / 20 respondents. 
 
Pain medication, most commonly non-steroidal anti-inflammatory drugs (n = 12) and paracetamol 
(acetaminophen) (n = 8), was used on a weekly or daily basis by 14/ 20 (70 %) respondents. Other analgesics were 
pregabalin ( n = 2), codeine (n = 1), tramadol (n = 1), oxycodone (n = 1) and amitriptyline (n = 1). The assessed 
median efficacy of current pain medication was 6 (IQR 4-8) on the NRS. 
 
Pain interference was highest in general activity (median 4.5, IQR 2-6.75 on the NRS) and normal work (median 4, 
IQR 3-7 on the NRS). Insomnia was reported by 8 responders. RAND-36 quality of life scores (Table 2) on the 
emotional and social domains were higher than the scores of physical domains. 
 
Discussion 
Exercise- and cold-induced, widespread pain was common in our cohort of patients. All respondents experienced 
pain during their course of illness. The severity and the impact of pain on daily life were variable. In this 
population, 27 % were incapacitated for work, compared to 6.4% of the Finnish general population.18 Pain 
interference was highest in the domains of general activity and normal work. 
 
 Half of the respondents reported pain less often than weekly. QoL subscales related to emotional well-being, 
emotional role functioning and social functioning were preserved, and severe depressive symptoms were rare. In 
this cohort of patients with a p.A1156T mutation, muscular symptoms dominated and other organ systems or 
mental health were much less affected. This is different than in myotonic dystrophy type 2 (DM2),16 in which pain 
was clearly associated with depressive symptoms and reduced emotional and social QoL. Also, in a previous 
cohort of patients with different SCN4A mutations (but not including p.A1156T) and DM2, QoL scores were higher 
in the SCN4 mutation group than in the DM2 group.9 
 
The exact mechanisms of pain in SCN4A mutation-associated channelopathies are not fully understood. Most 
SCN4A mutations cause gain-of-function defects, either disrupted inactivation or enhanced activation. 4 Mildly 
attenuated fast inactivation by the p.A1156T channel, demonstrated by functional studies, does not cause clinical 
myotonia or paramyotonia, although myotonic discharges had been detected by EMG in most such patients. 7 
Pain is reported in various proportions of myotonia patients with different SCN4A mutations.9,19,20  
 
Patients with certain muscular disorders, such as DM2 and myotonia congenita, can present with chronic 
widespread pain which may be indistinguishable from fibromyalgia.21,22,23 There is  evidence that EMG 
abnormalities in patients with myalgia can differentiate an underlying channelopathy from non-specific myalgic 
syndromes. 24 In our patients with the p.A1156T mutation, initial EMG studies showed either myotonic discharges 
or increased insertional activity, as published previously.7 
 
Diagnostic evaluations of non-myotonic dystrophies and many other genetic muscular syndromes can be 
challenging.9 The identification of a specific diagnosis underlying chronic widespread pain is important for 
avoiding wrong diagnoses, for precise nomenclature in daily practice and for future research on targeted 
pathophysiology and treatment. Multimodal and deconstructive strategies, such as the Research Domain Criteria 
(RDoC) framework, could help to integrate novel data on the research of the nature of complex phenomena 
including fibromyalgia and chronic pain.25,26 
 
There are several limitations in our study. The cross-sectional setting does not permit causal interpretations on 
the mechanisms of pain. The setting is also prone to recall bias. Both validated and customized instruments were 
used in this survey, which might have influenced the comparability of some of our results with previous research. 
 
 In conclusion, this channelopathy is another entity among the growing number of diseases causing widespread 
myalgic pain that resembles the pain of fibromyalgia syndrome. 
List of acronyms/abbreviations 
CLCN1 skeletal muscle voltage gated chloride channel gene 
DM2 myotonic dystrophy type 2 
IQR interquartile range 
Nav voltage-gated sodium channel 
NRS numerical rating scale  
QoL quality of life 
RAND-36 RAND 36-item Short Form Health Survey  
RBDI Finnish modification of the short form of the Beck Depression Inventory 
RDoC Research Domain Criteria 
SCN4A skeletal muscle voltage gated sodium channel gene 
WPI Widespread Pain Index 
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Table 1. Demographic and clinical characteristics of the respondents 
Respondent characteristics (n = 20)  
Age, median (range) 53 (20 – 79) 
Gender, female, n (%) 13 (65) 
Incapacitated for work, n (%)* 4 (27) 
Current pain reported, n (%) 16 (80) 
Pain previously but not currently, n (%) 4 (20) 
Depression scores (as measured by RBDI†)  
0 – 4 (no depression), n (%) 14 (70) 
5-7 (mild depression), n (%) 5 (25) 
8- 15 (moderate depression), n (%) 1 (5) 
16- 39 (severe depression), n (%) 0 (0) 
Pain intensity during the last week (NRS)‡  
At its worst, median (IQR§) 6 (5-8.75) 
On average, median (IQR§) 5 (4-6.75) 
At its least, median (IQR§) 1 (0-3) 
Occurrence of the most disturbing pain  
occasionally, n (%) 6 (30) 
monthly, n (%) 4 (20) 
weekly , n (%) 3 (15) 
daily, n (%) 5 (25) 
continuously, n (%) 2 (10) 
* Of working-age respondents (16–64 years, n = 15). 
† RBDI: The Finnish modification of the short form of the Beck Depression Inventory.  
‡ Measured by the Brief Pain Inventory (BPI). Numeric rating scale (NRS) 0-10, where 0: ‘‘no pain’’ and 10: ”worst 
possible pain”. 
§IQR: interquartile range. 
Table 2. Quality of Life RAND-36 scores and comparison to Finnish reference data* 
Subscale Study sample 
Median (IQR†) 
Study sample 
Mean (SD‡) 
General population § 
Mean (SD‡) 
p-value 
Role 
functioning/emotional 
100 (33.3-100) 68.4 (39.2) 75.0 (36.4) 0.47 
Social functioning 87.5 (53.13-100) 76.4 (30.9)  82.1 (23.2) 0.24 
Emotional well-being 80 (69-91) 76.4 (19.5)  73.7 (19.7) 0.54 
Physical functioning 61.1 (45-80) 61.4 (26.0)  84.9 (20.1) 0.001 
Energy 53.3 (35-76.67) 54.3 (20.9)  64.0 (22.4) 0.52 
General health 50 (37.5-58.75) 48.5 (17.3)  65.0 (19.8) <0.001 
Bodily pain 45 (35-73.75) 50.6 (24.5) 76.2 (24.0) <0.001 
Role 
functioning/physical 
25 (25-75) 36.3 (40.9)  74.8 (35.5) <0.001 
* Range 0-100, with higher scores indicating a better health state. 
† IQR: interquartile range. 
‡ SD: standard deviation. 
 
§Finnish general population values.13 
  
Figure Legends: 
Figure. Pain location and prevalence, data collected from pain drawings. 
 
 
 
 
